Bringing new animal vaccines to market requires more than just registering a ‘bug in a bottle’. The Australian Pesticides and Veterinary Medicines Authority, and other authorities around the globe, have strict regulations to ensure safety and that demand rigorous quality controls from vaccine seed to final product.
The Poultry CRC facilitates an industry collaboration that seeks to develop and commercialise next generation vaccines for infectious diseases in poultry.
Dr Joanne Devlin, from the Faculty of Veterinary and Agricultural Sciences, currently leads an unincorporated joint venture between seven participants, including the University of Melbourne and Bioproperties, which is executed through the Poultry CRC.
The cooperative work together to establish live vaccine candidates, ensures that they’re optimised for manufacture and develops them through safety and efficacy trials up to registration and commercialisation.
Bioproperties Pty Ltd is a member of the Poultry CRC and is a leading Australian novel vaccine research company, GMP manufacturer and global supplier of live vaccines to the intensively farmed food animal industry. The company was originally created in 1989 from IP generated within the University of Melbourne.
Bioproperties and The University of Melbourne have successfully cooperated closely during several Poultry CRC projects and have been responsible for the development of four individual poultry vaccines including the newly registered vaccine for fowl cholera, Vaxsafe® PM. As of mid-2015, there are four current ongoing projects including work focusing on infectious laryngotracheitis virus (ILTV), a contagious respiratory disease in poultry.
‘The CRC in part has formalised our company’s strategy of taking Australian inventions, and commercialising them utilising the University’s innovation and discovery talents, [while] Bioproperties strength is in scale up, registration and marketing.’ Chris Morrow, from Bioproperties Pty Ltd, said.